Menopause in Aesthetics (MiA) returns for its highly anticipated third year! After two groundbreaking events, MiA 2025 promises to push the boundaries of aesthetic medicine and menopause care. This ever-evolving conference and exhibition puts you at the forefront of one...
The diagnostic and therapeutic landscapes of prostate cancer (PCa) have advanced at great pace in the past decade. However, disparities in access to care, clinical outcomes and representation in therapeutic, interventional and genomic studies continue to exist between Afro-Caribbean (AC)...
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). For May/June, urology trainee Bushra Abdelqader is helping me to delve into that...
Dr. Vitor Cavadas, consultant urologist at CHUdSA Hospital, cannot wait to share his expertise and answer all your questions during lectures and even while he is operating.
Available separately to the four-volume Campbell-Walsh Urology (11th edition), is this Review edition. The hard copy appears substantial and roughly the same size as the other volumes, and is perhaps best considered the final volume and test of knowledge acquisition...
The Urology Foundation (TUF) is the only charity in the United Kingdom that raises money for research into all types of urological disease. Our ultimate aim as a charity is to discover the causes of urology cancers and conditions, to...
Founded in 1907, the SIU has established itself as the premier international professional society for urologists. As global interdependence increases, so does the relevance of the Society’s mission to enable urologists in all nations to apply the highest standards of...
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...
With the advent of one-stop prostate cancer diagnostic clinics, the findings of this study are of interest to readers who may be implementing MRI-US transrectal or transperineal fusion biopsies to their clinical practice. This prospective cohort study evaluated 779 consecutive...
In this issue of European Urology, Al-Monajjed et al. report findings from the PROBASE trial, which evaluated prostate cancer (PC) detection in men aged 45–50 years with PSA ≥3ng/ml using both MRI-targeted biopsy (TBx) and systematic biopsy (SBx). Among 525...
Look out for part 2 of this series later in 2016 when the author will discuss settling into the research role of his fellowship and will reflect on his first year overseas. This is the first in a series of...